Tony Raven

Tony Raven

Tony is the Chief Executive of Cambridge Enterprise, the commercialisation arm of the University of Cambridge.

In 1985 he was a founder of Summit Technology, the market leader in laser refractive surgery, which was acquired by Nestle Alcon in 2000 for $893 million. In 1987, he co-founded Cambridge-based Sagentia Group plc, a technical and management consultancy which is listed on the London Stock Exchange. In 1991 he founded Diomed Inc, a pioneer and world leader in therapeutic medical diode lasers, and served as CEO and Deputy Chairman until 2000. The company listed on the American Stock Exchange in 2002.

From 2000-2011 he was Director of Research and Innovation Services at the University of Southampton where he established with IP Group the first “patient capital” university investment fund, creating 11 spin-out companies with four listings on the London Stock Exchange.  He also created the model for SETsquared incubation which was ranked the Global #1 university business incubator in 2015.

Tony joined Cambridge Enterprise as CEO in 2011.  At Cambridge Enterprise he has focussed on engagement of the Arts, Humanities and Social Sciences in commercialisation and putting in place the investment funds to support the flow of new opportunities with a West Coast level of ambition.  These include the University of Cambridge Enterprise (seed) Fund for alumni (£8m to date), the £40m Apollo Therapeutics (proof of concept) Fund for developing new drug candidates and the £50m Cambridge Innovation Capital follow-on fund.  Income from commercialisation in 2015 is 240% of that in 2011.

Tony is a Fellow of the Institute of Physics and a Member of the Institute of Directors.